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KEY POINTS  
 Dasatinib, a potent TKI, combined with low-intensity chemotherapy gave 36% 5-year OS in Ph+ 
ALL patients over the age of 55 years.  A low co-morbidity score is prognostic for improved survival in this population.  Prospective monitoring of mutations may be useful to personalize therapy in Ph+ ALL patients 
not eligible for intensive therapy. 
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ABSTRACT 
Prognosis of Philadelphia-positive acute lymphoblastic leukemia (ALL) in the elderly improved during 
the imatinib era. We investigated dasatinib, another potent tyrosine kinase inhibitor, in combination 
with low-intensity chemotherapy. Patients older than 55 years were treated with dasatinib 140 mg/day 
(100 mg/day over 70 years) with intrathecal chemotherapy, vincristine and dexamethasone during 
induction. Patients in complete remission continued consolidation with dasatinib and reduced doses 
of sequential cytarabine and methotrexate for 6 months. Maintenance therapy was dasatinib and 
vincristine dexamethasone re-inductions for 18 months then dasatinib. Seventy-one patients with a 
median age of 69 years were enrolled, 77% had a high comorbidity score. Complete remission rate was 
96% and 65% of patients achieved a 3log reduction in BCR-ABL transcript levels (MMR) during 
consolidation. Seven patients (10%) underwent allogenic hematopoietic stem cell transplantation. At 
5-years, overall survival was 36% and up to 45% taking into account deaths unrelated to disease or 
treatment as competitors.  In multivariate analysis, a low CIRS-G score and MMR during consolidation 
were associated with longer overall survival. Thirty-six patients relapsed, 24 were tested for mutation 
by Sanger sequencing and 75% were T315I-positive. BCR-ABLT315I was tested by ASO RT-QPCR in 43 
patients and detection was associated with short-term relapses. Ten patients (23%) were positive 
before any therapy and eight relapsed, all with this mutation. In conclusion, dasatinib combined with 
low-intensity chemotherapy was well tolerated and gave long-term survival in 36% of elderly patients 
with Ph+ ALL. Monitoring of BCR-ABLT315I from diagnosis may help to switch therapy before 
hematologic relapse.  
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INTRODUCTION 
Philadelphia chromosome is the most frequent recurrent cytogenetic abnormality in elderly acute 
lymphoblastic leukemia (ALL) patients. Its incidence increases with age, reaching approximately 50% 
in ALL patients aged 60 years and over.1 Until the recent era of tyrosine kinase inhibitors (TKIs), most 
studies devoted to elderly patients with ALL made no distinction between Philadelphia chromosome-
positive (Ph+) and Philadelphia chromosome-negative cases. This was largely due to equally poor 
survival irrespective of Philadelphia chromosome status and the absence of differential treatments 
based on the identification of Ph+ ALL.2 The Ph chromosome arises from a reciprocal translocation 
between chromosomes 9 and 22 (t(9;22)(q34;q11.2)) fusing the c-ABL tyrosine kinase (TK) gene on 
chromosome 9 and the breakpoint cluster region (BCR) gene on chromosome 22. The deregulated 
BCR-ABL tyrosine kinase activity plays a major role in a transformation process in conjunction with 
other genetic alterations leading to a differentiation block giving rise to Ph+ (or BCR-ABL1 positive) 
ALL.3 
Designed as a targeted therapy against BCR-ABL tyrosine kinase activity, imatinib rapidly became a 
gold standard therapy in chronic myeloid leukemia and was proposed in relapsed/refractory Ph+ ALL.4 
The addition of imatinib to age-adapted chemotherapy significantly improved complete remission (CR) 
rates and disease-free survival as compared to historical controls in elderly Ph+ ALL patients.5 A 
randomized study from the German Multicenter Study Group for Adult ALL (GMALL) established the 
benefit of imatinib against a chemotherapy-based induction.6 To reduce toxicity, the Italian Group for 
Haematological Diseases in Adults (GIMEMA) proposed combining high-dose imatinib (800 mg/day) 
with prednisone, without chemotherapy.7 Preliminary data from the combination of high-dose 
imatinib with vincristine and dexamethasone (DIV regimen) suggested that a low-intensity 
chemotherapy approach was feasible and effective both in relapsed and in elderly Ph+ ALL patients.8 
The impact of new tyrosine kinase inhibitors, such as dasatinib or nilotinib, on the prognosis of Ph+ ALL 
is being prospectively assessed.9 Dasatinib is an oral, multi-targeted kinase inhibitor of the BCR-ABL 
and SRC family kinases, originally designed as an SRC kinase inhibitor. Dasatinib can bind to both the 
active and inactive conformations of the ABL kinase domain. Since it has less stringent binding 
requirements than imatinib, dasatinib has activity against many imatinib-resistant kinase domain 
mutations of BCR-ABL. One exception is the T315I mutation within the ATP-binding pocket of the ABL 
tyrosine kinase that confers a high degree of resistance.10 
The European Working Group on Adult ALL (EWALL) presented a consensus defining a low-intensity 
chemotherapy backbone for adult ALL patients aged 55 years and over, the ͞EWALL ďaĐkďoŶe͟. In the 
present study, we combined the EWALL backbone with dasatinib (Sprycel®, Bristol-Myers Squibb), for 
Ph+ ALL patients aged 55 years and over.  
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PATIENTS AND METHODS 
Study design and population 
EWALL-PH-01 is the first prospective phase 2 study conducted by the EWALL group on behalf of the 
European Leukemia Net. Patients aged 55 years or older were eligible if they had newly diagnosed Ph-
positive and/or BCR-ABL-positive ALL with or without documented central nervous system (CNS) 
involvement and if they had not been previously treated, except with corticosteroids or single dose 
vincristine. Patients had to have an Eastern Cooperative Oncology Group (ECOG) performance status 
of 0 to 3. Ineligibility criteria were QTc > 470 ms, heart insufficiency NYHA grade III/IV, left ventricular 
function <50%, myocardial infarction within 6 months prior to the study, active secondary malignancy 
or inadequate hepatic functioning defined as ASAT or ALAT > 2.5 times the institutional upper limit of 
normal (ULN) and total bilirubin > 2 x ULN unless due to organ involvement. Written informed consent 
was obtained from all patients. The study was approved in May 2007 by the institutional review board 
of Ile de France XI, France. The study was conducted in accordance with the Declaration of Helsinki 
(EudraCT: 2006-005694-21) and is registered on the EU Clinical Trial Web site 
(https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005694-21/FR). 
Study treatments 
The planned protocol is summarized in Figure 1. After a pre-phase, dasatinib was administered at 140 
mg QD during the induction period in combination with weekly vincristine 2 mg intravenous (IV) (1 mg 
for patients over 70 years) and dexamethasone 40 mg for 2 days (20 mg for patients over 70 years) for 
4 weeks. Consolidation consisted of dasatinib 100 mg/day sequentially with methotrexate 1000 mg/m² 
IV day 1 and asparaginase 10000 UI/m² IM day 2 for cycles 1, 3 and 5 and cytarabine 1000 mg/m²/12 
h IV day 1, day 3, day 5 for cycles 2, 4 and 6, with 4-week cycles. Maintenance consisted of dasatinib 
100 mg/day sequentially with 6-mercaptopurine (60 mg/m²/day) and methotrexate (25 mg/m²/week) 
orally, one every other month and dexamethasone/vincristine every 2 to 3 months up to 24 months. 
Post-maintenance therapy consisted of dasatinib alone (100 mg/m²/day) until relapse or death. The 
protocol allowed hematopoietic stem cell transplantation (HSCT) with reduced-intensity conditioning 
(RIC) or myeloablative conditioning (MAC) in eligible patients. CNS prophylaxis included alternating 
intrathecal therapy with methotrexate (15 mg), cytarabine (40 mg) and prednisone (40 mg) for a total 
of six injections (four during induction and two during consolidations). Due to an excess rate of 
treatment discontinuation in the first 11 patients over 70 years receiving dasatinib 140 mg/day, the 
protocol was amended after 15 months to reduce dasatinib and chemotherapy doses for patients aged 
70 years and older (dasatinib 100 mg/day during induction, methotrexate 500 mg/m², asparaginase 
5000 UI/m² and cytarabine 500 mg/m² during consolidations). Comorbidities were assessed at 
inclusion by the Cumulative Illness Rating Scale for Geriatrics comorbidity index (CIRS-G).11 
Molecular and cytogenetic assessments  
Patients were monitored for BCR-ABL by RTQ-PCR in national central laboratories in each country in 
accordance with current recommendations.12 Minimal residual disease (MRD) was assessed after 
induction (MRD1), during consolidation (MRD2) and throughout maintenance. Bone marrow (BM) 
results were considered preferentially when results from both peripheral blood (PB) and BM were 
available. In the absence of a BM sample, PB results were analyzed if available. During consolidation, 
the highest BCR-ABL value was considered to define MRD2.  
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Methods for BCR-ABLT315I ASO RTQ-PCR are described in the supplemental appendix. A sensitivity 
threshold of 0.05% was chosen, corresponding to the upper limit of the 95% confidence interval (CI) 
estimated from the distribution of non-specific signals measured in 60 samples that were negative for 
BCR-ABL1T315I. Cytogenetic analyses were performed in each local laboratory at diagnosis and were 
reviewed centrally according to the classification proposed by Heerema et al.13 
Response definitions 
Complete hematologic remission (CR) was defined as the presence of 5% or less blasts in the bone 
marrow, with a gƌaŶuloĐǇte ĐouŶt ≥ 1.0 × 109/L, platelet ĐouŶt ≥ 100 × 109/L and no extramedullary 
disease. Molecular response 5 log (MR5) was defined by a 5 log reduction in BCR-ABL transcript level. 
Major molecular response (MMR) was defined by a BCR-ABL/ABL ratio <0.1%. Relapse was defined by 
recurrence of more than 5% lymphoblasts in the bone marrow aspirate or by the presence of 
extramedullary disease after achieving CR. Induction death was defined as death occurring after start 
of therapy without meeting the definition of CR or resistant disease. Resistant disease included 
patients who survived the induction treatment period but had persistent leukemia. Relapse-free 
survival (RFS) was calculated from the first day of therapy to the relapse date. Event-free survival (EFS) 
was defined as the time between randomization and primary refractoriness, hematologic relapse or 
death in first CR, other patients being censored at the time of last contact. Overall survival (OS) was 
calculated from the date of initiation of therapy until death. Toxicity was evaluated according to the 
National Cancer Institute Common Toxicity Criteria Version 2.0.55.  
Statistical methods 
The primary endpoint was RFS at 12 months. Patients in remission were censored at the time of last 
follow-up. A sample size of at least 50 patients was calculated ďǇ FleŵiŶg’s siŶgle-stage design to 
ensure 80% power for proving lack of efficacy if the true CR rate was below 60%. Considering a rate 
below 40% would imply lack of efficacy, a sample size of at least 48 patients had to be recruited to 
detect a remission rate > 60% with 80% power and a leǀel of α=Ϯ.5% ;oŶe-sided test). Allowing for 
potential censured data, a total of 55 patients were planned. This number was subsequently increased 
to 71 patients by amendment to compensate for early treatment discontinuation seen in patients aged 
over 70 years. Secondary endpoints were cumulative incidence of relapse (CIR), cumulative incidence 
of non-relapse related mortality, and OS. The Kaplan-Meier method was used to estimate the EFS, RFS 
and OS probabilities. Hazard ratios (HRs) were given with the 95% confidence interval (CI). Analysis 
followed the intent-to-treat (ITT) principle. Baseline characteristics were compared by non-parametric 
tests, either the exact Fisher's test for qualitative variables and the Kruskal-Wallis test for quantitative 
variables. The censored endpoints (time to death, RFS) were estimated by the non-parametric Kaplan-
Meier method with a 95% CI. Cumulative incidences were estimated using Aalen estimator.14 
Prognostic factors of survival and progression-free survival (PFS) were investigated using Cox 
proportional hazard models. Statistical analysis was performed with XLSTAT software (version 
2014.2.03, Addinsoft) and R Project for Statistical Computing software (R version 2.15.2). M.D. and 
Ph.R analyzed the data and all authors had access to primary clinical trial data.  
RESULTS 
Patient characteristics  
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Seventy-one patients were included between August 2007 and July 2010. One patient had CNS 
involvement at diagnosis (Table 1). Median age was 69 years (range, 59 to 83) and the sex ratio (M/F) 
was 0.73. Median follow-up on study was 32 months (range, 2 to 88 months) and median follow-up 
for surviving patient was 66 months (range, 21 to 88 months) at the time of analysis in January 2015. 
Median CIRS-G score value was 6 (range, 0 to 16). Overall, 77% of the patients had a CIRS-G score >4. 
Karyotype analysis was performed in all patients and cytogenetic results were evaluable in 63 (90%). 
All evaluable patients had the t(9;22) chromosomal translocation and 48 (76%) presented with 
additional cytogenetic aberrations (ACAs). BCR-ABL RQ-PCR was available in all patients. Minor 
breakpoint transcripts e1a2 and e1a3 encoding for the p190BCR-ABL protein were identified in 54 patients 
(76%). Major breakpoint transcripts e13a2 and e14a2 encoding the p210BCR-ABL protein were identified 
in 17 patients (24%). 
Response to therapy and outcome 
Sixty-seven of the 71 patients (96%) achieved CR. Four patients failed to obtain CR, one was refractory 
and obtained CR after salvage therapy and three died during induction. Among the 67 patients in CR 
after induction, 36 relapsed (54%). Ten patients obtained a second CR (28%), six of whom relapsed 
again. Forty-nine patients died (69% of the total population) including 32 deaths in relapse or 
refractory disease and 14 deaths in CR (non-relapse related mortality 29%). Treatment-related 
mortality was reported in six patients (12%). Eight deaths were unrelated to disease or therapy 
(including three late deaths, two from adenocarcinoma after 49 and 66 months in study and one from 
meningioma after 68 months). Twenty-two patients (31% of the total population) were alive at the 
time of analysis. Seven patients underwent allogenic HSCT, five with RIC and two with MAC. Three 
patients relapsed after transplant at 4.6, 6.3 and 6.5 months and died, four patients were alive at 53, 
56, 59 and 65 months. Figure 2 summarizes treatment outcomes.  
Among the 67 patients in first CR, 55 (82%) were evaluable for MRD1. Characteristics of these 55 
patients did not differ from those of the 12 CR patients not tested. Thirty-three patients reached MMR 
(60%) and 11 patients reached MR5 (20%). At MRD2, 36 patients reached MMR (65%) and 13 patients 
reached MR5 (24%).  
RFS at 12 months was 58% [95% CI, 45-69]. At 3 years, RFS, EFS and OS were 33% [95% CI, 22-44], 31% 
[95% CI, 21-42] and 41% [95% CI, 29-52] respectively. At 5 years RFS, EFS and OS were 28% [95% CI, 
18-39], 27% [95% CI, 17-37] and 36% [95% CI, 25-47] respectively. Median RFS, EFS and OS were 19.1, 
18.9 and 25.8 months respectively. Taking into account deaths unrelated to disease or treatment as 
competitors, OS was 45% [95% CI, 43- 67] at 5 years (Figure 3B). Taking allogenic HSCT as competing 
events did not impact RFS, EFS or OS (Supplementary Figure 1). 
Safety 
Median time on dasatinib therapy was 7.8 months (range 0.6-72.4). The cumulative incidence of 
dasatinib discontinuation for any reason is illustrated in Supplementary Figure 3. Twelve out of 22 
patients alive were still on dasatinib at the time of analysis (54%). The other ten patients were being 
treated with imatinib or nilotinib.  
During induction, the mean duration of neutropenia < 0.5 G/L was 8.9 days (range, 0 to 41 days) and 
mean duration of fever > 38.5°C was 3.3 days (range, 0 to 10 days). G-CSF was administered to 73% of 
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the patients and 23 patients (32%) did not experience neutropenia. Mean duration of large spectrum 
antibiotics was 12 days. Thirteen patients presented bacteremia or septicemia (four with gram-
negative and nine with gram-positive strands). Two patients developed nonbacterial lung infections 
(one pneumonia with Pneumocystis jirovecii and one Aspergillosis). Mean duration of platelets <20 G/L 
was 3 days (range, 0 to 41 days). Consolidations with methotrexate and asparaginase were associated 
with very few episodes of neutropenia (two during consolidation 1, two during consolidation 3, and 
none during consolidation 5). Consolidation with intermediate-dose cytarabine was associated with a 
mean duration of neutropenia < 0.5 G/L of 4.2 days, 5.9 days and 6.3 days during consolidation 2, 4 
and 6, respectively, and a mean duration of platelets < 20 G/L of 3.2 days, 4.5 days and 4.9 days, 
respectively. During maintenance, 11 patients presented short episodes of neutropenia < 0.5 G/L.  
Pleural effusion occurred in seven patients (10%), including three cases during induction, two cases 
during consolidation, one case during maintenance and one case during post-maintenance therapy 
with dasatinib. The median age of patients with pleural effusion was the same as that of patients 
without. No concomitant lymphocytosis was seen. Median latency was 2.3 months with only one late 
case (after 60.7 months). Three patients were receiving 140 mg/day and four 100 mg/day at the onset 
of pleural effusion was 100 mg/day. Median duration of pleural effusion was 13 days (range, 4 to 41 
days). As has previously been reported elsewhere,15 four cases were associated with interstitial 
pneumonia and one case with pericardial effusion. In the late-occurring case there was a strong 
suspicion of pulmonary hypertension on an echocardiography in this patient also diagnosed with 
peritoneal carcinomatosis (Supplementary Table 2). Of note, RFS of patients who experienced pleural 
effusion was not different to those without (Supplementary Figure 2).  
Other serious adverse events included tumor lysis syndrome during induction (n=2), renal failure (n=6), 
subdural hemorrhage (n=3, including one patient with concomitant acetyl salicylic acid therapy), 
digestive hemorrhage (n=3), transaminase elevations (n=5), pulmonary embolism (n=3), atrial 
fibrillation (n=4), and cardiac failure (n=2).  
Relapses and mutations 
Thirty-six relapses were observed including 14 during consolidation, 19 during maintenance and 3 after 
allogenic HSCT. Cumulative incidence of relapse was 54% [95% CI, 42-66] at 5 years. Standard mutation 
analysis with Sanger sequencing was available at relapse for 24 patients: 18 relapses were associated 
with the T315I mutation (including one compound mutation T315I+M244V+E255K), one relapse was 
associated with the F317L mutation, one with the V299L, one with a compound mutation without 
T315I, and mutations were not detectable in three patients. Sanger sequencing was not performed in 
12 patients at relapse but ASO PCR for the detection of BCR-ABLT315I was negative in all seven patients 
tested (Figure 4).  
ASO PCR for the detection of BCR-ABLT315I was retrospectively performed in 43 patients on 
prospectively-collected RNA samples. No significant differences were seen between tested and non-
tested patients in terms of baseline characteristics. Of these 43 patients, 10 (23%) were BCR-ABLT315I-
positive by ASO PCR at the sensitivity level of 0.05% before any therapy (Figure 5). No mutation was 
detectable by Sanger sequencing on these samples. Eight patients relapsed, all with the T315I mutation 
including one relapse 4 months after allogenic HSCT. During follow-up, BCR-ABLT315I was detected 1 to 
3 months before hematologic relapse. Two patients did not relapse, one patient was transplanted and 
was still in CR 54 months after allogenic HSCT, and the other died in CR at 9.6 months from lung 
10 
 
adenocarcinoma. We compared the cumulative incidence of relapse (death was considered as a 
competing risk) between T315I mutated (BCR-ABLT315I) and other patients at diagnosis. Quicker 
relapses were observed in cases of a detectable BCR-ABLT315I (median 7 months) as compared to 
other patients (median not reached) (Fine and Gray regression coefficient: 14.80 (95%CI, [7.03-31.20]), 
p<0.001 (Figure 6). 
Prognostic factors 
Univariate and multivariate analyses were performed including age and CIRS-G score (continuous 
variables), sex, leukocytes <30 x109/L, karyotype, BCR breakpoint, BCR-ABLT315I at diagnosis, and 
molecular response status at MRD1 and MRD2. In univariate analysis, younger age (HR, 0.95 [95% CI, 
0.90-0.99]; p=0.048), female gender (HR, 0.46 [95% CI, 0.23-0.77]; p=0.0058), leukocytes <30 x109/L 
(HR, 0.52 [95% CI, 0.26-0.90]; p=0.002), and no BCR-ABLT315I at diagnosis (HR, 0.43 [95% CI, 0.12-0.83]; 
p=0.002) were associated with longer OS. Better RFS was associated with leukocytes <30 x109/L (HR, 
0.56 [95% CI, 0.28-0.97]; p=0.04), no ACAs (HR, 0.45 [95% CI, 0.27-0.95]; p=0.03), no BCR-ABLT315I at 
diagnosis (HR, 0.43 [95% CI, 0.11-0.91]; p=0.03) and achievement of MMR at MRD2 (HR, 0.45 [95% CI, 
0.15-0.85]; p=0.02). 
Detection of BCR-ABLT315I at diagnosis was excluded from the multivariate analysis given that all 
patients were not tested. For OS, female gender (HR, 0.28 [95% CI, 0.13-0.63]; p=0.002), a low CIRS-G 
score (HR, 0.79 [95% CI, 0.69-0.91]; p=0.001), and achievement of MMR at MRD2 (HR, 0.31 [95% CI, 
0.12-0.78]; p=0.013) were associated with increased OS. Similarly, a low CIRS-G score (HR, 0.76 [95% 
CI, 0.65-0.90]; p=0.001) and achievement of MMR at MRD2 (HR, 0.17 [95% CI, 0.06-0.51; p=0.002) were 
associated with longer RFS. A trend was observed for longer RFS in patients without ACAs (p=0.05). 
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DISCUSSION 
This study reports the long term outcome of elderly Ph+ ALL patients treated with dasatinib, a second 
generation TKI in combination with low-intensity chemotherapy. Complete remission was achieved in 
96% of the patients, RFS at 12 months was 58% and 5-year overall survival 36%.  
Relatively few studies have specifically investigated the use of imatinib in combination with 
chemotherapy in Ph+ ALL in the elderly. The GIMEMA proposed a study in Ph+ ALL patients aged more 
than 60 years evaluating the use of steroids combined with high-dose imatinib (800 mg/day), without 
additional chemotherapy. Complete remission was obtained in all 29 patients with low toxicity 
however remission duration was limited in patients not eligible for allogenic HSCT.7 The GMALL group 
performed a randomized study assessing induction therapy with either imatinib or multi-agent, age-
adapted chemotherapy followed by imatinib administered with consolidation chemotherapy in both 
arms. The overall CR rate was 96% in patients assigned to imatinib and 50% in patients allocated to 
chemotherapy. OS was not significantly different between the two cohorts.6 A low-intensity schedule 
(vincristine and dexamethasone) in combination with high-dose imatinib (800 mg/day) was proposed 
in the GRAALL AFR07 study for patients aged more than 55 years (DIV regimen).8 A pilot study of this 
combination showed promising results in relapsing and refractory Ph+ ALL with a CR rate of 90% in 
patients older than 55 years suggesting that high-dose chemotherapy may not be needed in this 
population. 
The question as to whether dasatinib improves the prognosis of Ph+ ALL patients has been investigated 
in a few studies. The GIMEMA group tested an induction regimen combining dasatinib at the initial 
dose of 70 mg twice daily with intrathecal chemotherapy and steroids for 84 days.16 All 53 patients 
(median age 54 years) achieved CR, and disease-free survival was 51% at 20 months despite intensive 
consolidation therapies in 60% of the patients. A second study tested the combination of intermittent 
dasatinib (100 to 140 mg/day) with the hyper-CVAD regimen in 72 patients (median age 55 years). 
Response rate was 96% and long term survival was 46% with a median follow-up of 67 months for 
surviving patients.17 The median age of the patients included in the current EWALL-PH-01 study (69 
years) is the oldest reported to date in a large cohort. This elderly group of patients had a very low rate 
of allogenic HSCT (10%). In this setting, the combination of dasatinib with low-intensity chemotherapy 
gave 5-year OS of 36%, suggesting that a subgroup of elderly patients may experience long-term 
survival without the need for intensive therapies.  
The achievement of MMR during consolidation (MRD2) was a strong predictor for OS and RFS in this 
study, which is contrary to other reports that MMR after induction has not shown prognostic value.18 
Sixty-five percent of the patients reached MMR at MRD2, a proportion similar to that observed in the 
GRAAPH study for young patients using imatinib and intensive consolidation.19 The deep molecular 
response rate was also comparable suggesting that molecular response can also be achieved with a 
more potent TKI without the need for intensive consolidation regimens. 
This is the first demonstration of the comorbidity score (CIRS-G) as a prognostic factor for survival in 
elderly Ph+ ALL. Overall, 77% of the patients included in the EWALL-PH-01 study had a CIRS-G score > 
4, highlighting the growing importance of deaths unrelated to the disease in elderly patients. Eight of 
the patients died from causes independent of ALL or therapy. Five-year OS was 45% taking into account 
deaths unrelated to disease or treatment as competitors.  
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Safety was acceptable in this elderly population, especially after the reduction of dasatinib daily dose 
from 140 to 100 mg/day for patients aged 70 years or more. Despite the use of a more potent TKI, the 
rate of induction deaths was low (4%). Treatment-related mortality (12%) compares favorably with 
previous studies using more intensive chemotherapy.7 Pleural effusions are age and dose-dependent 
in patients treated with dasatinib. Recent long-term follow-up studies reported an incidence of 28% to 
35% at 5 years in CML patients treated with imatinib compared to only 10% in our aged ALL 
population.20 This low rate of pleural effusions in our study is likely related to the concomitant 
administration steroids and immunosuppressive chemotherapy.  
Relapses were associated with clones harboring mutations known to confer a high degree of resistance 
to dasatinib, as previously described.21 Sanger sequencing was performed in 24out of 36 relapses and 
the T315I mutation was present in 18 of 24 relapsing patients (75%). Other mutations which may be 
selected by dasatinib were identified such as the V299L mutation (one case) and the F317L mutation 
(one case). With a specific ASO-PCR for the detection of BCR-ABLT315I, we were able to search for the 
T315I mutation at diagnosis in 43 patients. Ten patients (23%) were found to be positive. For the first 
time, we have been able to assign a negative prognostic value of this finding at the level of sensitivity 
of 0.05%. Eighty percent of the patients detected with positive BCR-ABLT315I ASO-PCR relapsed except 
two patients, one who died in CR during maintenance and one who underwent allogenic HSCT. 
Similarly, 80% of the patients detected as BCR-ABLT315I-positive during follow-up relapsed one to three 
months after detection.  
Whether the use of more powerful BCR-ABL inhibitors such as ponatinib may improve OS in Ph+ ALL 
remains to be determined. The cardiovascular toxicity of ponatinib may counteract the potential 
benefit of this drug in an elderly population with a high comorbidity index, such as that of the EWALL-
PH-01 study. A tailored choice based on patient status and adverse disease-related risk factors, such 
as the monitoring of mutations, could be one way to balance risk and efficacy in future trials.  
In conclusion, we report high efficacy of dasatinib combined with low-intensity chemotherapy (EWALL 
backbone) in elderly Ph+ ALL patients with a 36% long-term survival without the need for intensive 
chemotherapy or allogenic HSCT. These good-risk patients are defined by a low MRD2 level and a low 
comorbidity score. We report the first evidence supporting prospective monitoring of the T315I 
mutation in patients not eligible for intensive therapies in order to personalize therapy before 
hematologic relapse.  
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TABLES AND FIGURES 
Table 1. Patient characteristics 
 Patients (n=71) 
Baseline  
Male/female, n 30/41 
Median age, y (range) 69 (59-83) 
ECOG PS 0/1/2/3, n 21/44/5/1 
Median CIRS (range) 6 (0-16) 
CIRS-G > 4, n (%)* 54 (77%) 
CNS disease, n (%)* 1 (1%) 
Median WBC, 109/L (range) 12.4 (0.8-348.3) 
WBC ≥ϯϬ ǆ ϭϬ9/L, n (%) 27 (38) 
Karyotype**  
Non evaluable, n (%) 8 (11%) 
t(9;22) + no secondary aberration, n (%) 15 (21%) 
t(9;22) + loss and/or gain, n (%) 31 (44%) 
Loss (del(7p), -7, del(9p)) 12 (17%) 
Gain (+Ph, High Hyperdiploidy) 11 (15%) 
Loss and gain 8 (11%) 
t(9;22) + others 17 (24%) 
Molecular biology, n  
Bcr subtype (m/M/both) 54/17/0 
ECOG PS, Eastern Cooperative Group performance status; CIRS, cumulative illness rating scale; WBC, 
white blood cell count; *n=70; ** according to Heerema NA et al.13 ; Del(7)p, deletion 7p; -7, monosomy 
7; del(9p), deletion 9p; +Ph, duplication of the Ph chromosome; Bcr, BCR-ABL breakpoint; m, minor 
breakpoint; M, major breakpoint.   
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Figure 1. EWALL-PH-01 treatment strategy  
 
PCR analysis; ASP, asparaginase; IDAC, intermediate-dose cytarabine; Cons., consolidation; Dasa, 
dasatinib; DEXA, dexamethasone; IDMTX, intermediate-dose methotrexate; IT, intrathecal (triple IT, 
15 mg MTX, 40 mg AraC and 40 mg prednisone); 6MP, 6-mercaptopurine; MTX, methotrexate; mo, 
month; P, pre-phase; QD, once a day; VCR, vincristine.   
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Figure 2. Consort diagram.  
 
Ph+ ALL, Philadelphia chromosome (or BCR-ABL) positive acute lymphoblastic leukemia; CR, complete 
remission; CR1, complete remission 1; CR2, complete remission 2; Allo HSCT, allogenic hematopoietic 
stem cells transplantations; TRM, treatment related mortality; pts, patients.  
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Figure 3. Overall survival (3A, n=71) and overall survival taking into account deaths unrelated to 
disease or treatment as competitors (3B, n=71), event-free survival (3C, n=71), and relapse-free 
survival (3D, n=67).  
3A. 
 
3B. 
 
3C. 
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3D. 
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Figure 4. Distribution of BCR-ABL tyrosine kinase domain mutations in patients in first relapse.  
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Figure 5. Follow-up of 10 patients positive for BCR-ABLT315I by ASO PCR at inclusion.  
 
Allo HSCT, allogenic hematopoietic stem cell transplantation; Post M, post maintenance;     BCR-
ABLT315I detected by ASO PCR at diagnosis;      BCR-ABLT315I not detected by ASO PCR during follow-
up;      BCR-ABLT315I detected by ASO PCR during follow-up without hematologic relapse;    , BCR-
ABLT315I detected by ASO PCR and Sanger sequencing at hematologic relapse.  
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Figure 6. Cumulative incidence of relapse in all 67 patients in CR (6A) and in patients with BCR-ABLT315I 
> 0.05% as compared to other patients (6B) (Regression coefficient: 14.80 (95% IC, [7.03-31.2], p < 
0.001). 
6A 
 
6B.  
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Supplementary appendix 
Supplementary methods  
For C944T(T315I) ASO RTQ-PCR, after extraction with TRIzol (Invitrogen) total RNA was titrated to 1 
μg/μL ǁith a NaŶoDƌop ϮϬϬϬĐ UV-Vis spectrophotometer (ThermoScientific) and stored at -80°C. 
Complementary DNA (cDNA) was synthesized from 1 μg RNA ǁith a ƌeǀeƌse tƌaŶsĐƌiptase M-MLV Kit® 
(Life Technologies) using Random Hexamer Primers (ThermoScientific). RTQ-PCR (BCR-ABL1, ABL1) was 
peƌfoƌŵed iŶ Ϯ5 μl fƌoŵ oŶe-tenth of the cDNA volume (100 ng RNA), using a thermocycler ABI7900HT 
(Life Technologies) with TaqMan reagent (Life Technologies) in standard mode (1 cycle of 2 minutes at 
50°C then 10 minutes at 95°C followed by 50 cycles of 15 seconds at 95°C then 1 minute at 60°C). A 
highly sensitive allele-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO 
RTQ-PCR) was used to quantify the BCR-ABL1T315I tƌaŶsĐƌipt ƌatio. The A“O ;5’-GAGCCCCCGTTCTATAT- 
CATGAT-ϯ’Ϳ primer included one mismatch with the T315I allele (T) and two with the wild type allele 
;G aŶd TͿ. This A“O ǁas used as foƌǁaƌd pƌiŵeƌ, ǁith ƌeǀeƌse pƌiŵeƌ 5’-CGTTCACCTC CTGCCGG-ϯ’ aŶd 
TaƋŵaŶ pƌoďe 5’-FAM-CCCTTCAGC GGCCAGTAGCATCTGA-TAMRA-ϯ’. ASO RTQ-PCR reaction was 
peƌfoƌŵed iŶ Ϯ5 μl fƌoŵ oŶe-tenth of the cDNA volume (100 ng RNA) using the same reagent in a 
thermocycler, the only difference being an annealing temperature of 63°C. As the PCR efficiency was 
comparable between the two RTQ-PCR systems (BCR-ABL1T315I and ABL1), results are expressed as 
percentages of BCR-ABL1T315I and ABL1 copy number ratios (BCR-ABL1T315I/ABLϭ%Ϳ, usiŶg the ΔCt 
method. 
Supplementary Table 2. Pleural effusions associated with dasatinib.  
Patient Age, y Sex Dasatinib daily 
dose, mg/day 
Latency, 
months 
Associated 
symptoms 
Grade Pleural fluid 
1 71 F 140 1.7 Pneumonia 3 Exudate 
2 68 F 140 0.2 Pericarditis 2 ND 
3 74 M 140 1.2 Pneumonia 3 ND 
4 66 F 100 2.3 Pneumonia 2 ND 
5 76 F 100 8.5 Bronchitis 2 ND 
6 71 F 100 60.7 PAH 4 Exudate 
7 65 M 100 4.2 None 3 Exudate 
PAH, pulmonary arterial hypertension; M, male; F, female; ND, not done;  
 
Supplementary Figure 1. Overall survival (OS, n=71)(S1A), event-free survival (EFS, n=71)(S1B) and 
relapse-free survival (RFS, n=67)(S1C) with and without censoring for allogenic HSCT. HR for OS: 0.92 
[95% CI, 0.61-1.37]; p=0.68; HR for EFS: 0.95 [95% CI, 0.64-1.39]; HR for RFS: 0.94 [95% CI, 0.63-1.42].     
S1A 
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S1C 
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Supplementary Figure 2: Relapse-free survival in patients with (continuous line) or without (dashed 
line) pleural effusion (PE); p=0.6 by the Log-rank (Mantel-Cox) test.  
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Supplementary Figure 3: Cumulative incidence of dasatinib discontinuation.  
 
 
 
 
